推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733，021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults

N Binkley, D Gemar, J Engelke… - Journal of Clinical …, 2011 - Endocrine Soc
Address all correspondence and requests for reprints to: Neil Binkley, MD, University of Wisconsin
Osteoporosis Research Program, 2870 University Avenue, Suite 100, Madison, Wisconsin
53705. E-mail: nbinkley{at}wisc.edu. ... Context:Whether ergocalciferol (D 2 ) and ...
Cited by 4 - Related articles - All 3 versions

Paricalcitol Versus Ergocalciferol for Secondary Hyperparathyroidism in CKD Stages 3 and 4: A Randomized Controlled Trial

CP Kovesdy, JL Lu, SM Malakauskas… - American Journal of …, 2011 - Elsevier
The efficacy of 25-hydroxyvitamin D (25[OH]D) supplementation versus vitamin D receptor activators
for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease
(CKD) stages 3 or 4 and vitamin D deficiency is unclear. ... 80 patients with CKD stages ...

152 Ergocalciferol (ERGO) Therapy in Calcidiol-Deficient Hemodialysis (HD) Patients on Therapeutic Doses of Paricalcitol

VMR Krishnamurthy, CM Terry… - American Journal of …, 2011 - urologyaccess.org
No abstract is available. To read the body of this article, please view the PDF online. ... © 2011
National Kidney Foundation, Inc. Published by Elsevier Inc All rights reserved. ... Visit SciVerse
ScienceDirect to see if you have access via your institution. ... Advertisements on this site ...
Cached - All 5 versions

[CITATION] Daily amount of vitamin D (D) would be given an important factor to equal the effectiveness of cholecalciferol and ergocalciferol

MMS Gonzales Chaves, C Marotte, GG Pellegrini… - Bone, 2011 - Elsevier

Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines

L Brard, TS Lange, K Robison, KK Kim, T Ara… - Gynecologic …, 2011 - Elsevier
We modified the Ergocalciferol structure to generate MT19c, a heterocyclic vitamin-D
derivative. Hypercalcemic liabilities of MT19c were assessed by estimating the blood calcium
levels in drug treated animals. VDR agonistic or antagonistic properties of MT19c were ...

联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

© 2010-2024 中国: LetPub上海分公司    网站备案号：沪ICP备10217908号-1    沪公网安备号：31010402006960

增值电信业务经营许可证：沪B2-20211595

礼翰商务信息咨询（上海）有限公司      办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室

United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451